IN2012DN01984A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01984A
IN2012DN01984A IN1984DEN2012A IN2012DN01984A IN 2012DN01984 A IN2012DN01984 A IN 2012DN01984A IN 1984DEN2012 A IN1984DEN2012 A IN 1984DEN2012A IN 2012DN01984 A IN2012DN01984 A IN 2012DN01984A
Authority
IN
India
Prior art keywords
tfpi
aptamers
bind
disorders
nostics
Prior art date
Application number
Inventor
G Schaub Robert
Mcginness Kathleen
Nelson Jennifer
Genga Ryan
Waters Emily
C Kurz Jeffrey
L Diener John
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of IN2012DN01984A publication Critical patent/IN2012DN01984A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The invention relates gener¬ally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diag¬nostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI ap¬tamers may be used before, during and/or af¬ter medical procedures to reduce complica¬tions or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
IN1984DEN2012 2009-08-18 2010-08-17 IN2012DN01984A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23493909P 2009-08-18 2009-08-18
US35337410P 2010-06-10 2010-06-10
US36636210P 2010-07-21 2010-07-21
US36776610P 2010-07-26 2010-07-26
PCT/US2010/045797 WO2011022427A1 (en) 2009-08-18 2010-08-17 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Publications (1)

Publication Number Publication Date
IN2012DN01984A true IN2012DN01984A (en) 2015-07-24

Family

ID=43607310

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1984DEN2012 IN2012DN01984A (en) 2009-08-18 2010-08-17

Country Status (17)

Country Link
US (1) US8252913B2 (en)
EP (1) EP2467167B1 (en)
JP (1) JP2013502218A (en)
KR (1) KR20120061086A (en)
CN (1) CN102869385A (en)
AU (1) AU2010284329B2 (en)
BR (1) BR112012003806A2 (en)
CA (1) CA2770762A1 (en)
CO (1) CO6531414A2 (en)
ES (1) ES2655589T3 (en)
IL (1) IL218048A0 (en)
IN (1) IN2012DN01984A (en)
MX (1) MX2012002133A (en)
NZ (1) NZ598557A (en)
RU (1) RU2012110221A (en)
SG (1) SG178408A1 (en)
WO (1) WO2011022427A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
WO2012109675A1 (en) * 2011-02-11 2012-08-16 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
KR20140066977A (en) 2011-06-08 2014-06-03 미에드지나로도위 인스티투트 바이오로지 모레쿠라네지 아이 코모르코웨즈 Sequence-specific engineered ribonuclease h and the method for determining the sequence preference of dna-rna hybrid binding proteins
AU2013235567A1 (en) * 2012-03-22 2014-10-09 Baxalta GmbH Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
DE102012020496A1 (en) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Invitro diagnosis and/or early detection of neurofibromatosis type 1 and/or neurofibromatosis type 1-associated tumor from sample of a patient for treating the patient with the tumor, comprises detecting protein or its fragment in sample
JP6502930B2 (en) * 2013-06-21 2019-04-17 イミジン， インコーポレイテッド Blood analysis
EP3022228B1 (en) 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
EP3044334B1 (en) * 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
MX390848B (en) * 2015-06-23 2025-03-21 Childrens Hospital Philadelphia MODIFIED FACTOR IX, AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS AND TISSUES.
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN108368509B (en) * 2015-12-04 2022-03-22 全药工业株式会社 Anti-IL-17 aptamer with improved blood retention
CN112442127A (en) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 Monoclonal Antibody Against TFPI
CN115792231B (en) * 2022-11-04 2023-07-25 中拓生物有限公司 DNase I biosensor based on thrombin aptamer-regulated enzyme cascade reaction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
JP4663113B2 (en) * 1997-09-05 2011-03-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation
EP1020534B2 (en) * 1998-11-09 2011-01-05 Eiken Kagaku Kabushiki Kaisha Process for synthesizing nucleic acid
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
WO2003102212A2 (en) * 2002-05-31 2003-12-11 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP1919499A2 (en) 2005-07-29 2008-05-14 Universiteit van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor

Also Published As

Publication number Publication date
JP2013502218A (en) 2013-01-24
RU2012110221A (en) 2013-09-27
MX2012002133A (en) 2013-02-15
US8252913B2 (en) 2012-08-28
ES2655589T3 (en) 2018-02-20
CO6531414A2 (en) 2012-09-28
EP2467167A4 (en) 2013-12-25
IL218048A0 (en) 2012-04-30
EP2467167A1 (en) 2012-06-27
US20110098345A1 (en) 2011-04-28
BR112012003806A2 (en) 2016-11-16
WO2011022427A1 (en) 2011-02-24
AU2010284329B2 (en) 2015-04-16
NZ598557A (en) 2013-08-30
CA2770762A1 (en) 2011-02-24
KR20120061086A (en) 2012-06-12
EP2467167B1 (en) 2017-08-16
AU2010284329A1 (en) 2012-03-29
CN102869385A (en) 2013-01-09
SG178408A1 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
IN2012DN01984A (en)
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12012501838A1 (en) Aptamers to ãŸ-ngf and their use in treating ãŸ-ngf mediated diseases and disorders
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
WO2013151736A3 (en) In vivo production of proteins
MY169987A (en) Selective pi3k delta inhibitors
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012138487A3 (en) Oligonucleotide modulation of splicing
WO2011060049A3 (en) Spiro-oxindole mdm2 antagonists
HK1243322A1 (en) Fatty acid cysteamine conjugates and their use as activators of autophagy
MX379446B (en) Anti-Activin A Antibodies and Their Uses
PH12014501108A1 (en) Anti-il-36r antibodies
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
PH12012502523A1 (en) Dual variable domain immunoglobulins and uses thereof
HK1198358A1 (en) Sustained release composition of prostacyclin
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
SG10201804817TA (en) Delayed release compositions of linaclotide
WO2013055899A3 (en) Compositions useful in treating nephropathy and methods for preparation of same
WO2012125981A3 (en) Raf kinase inhibitors
WO2013106689A8 (en) Hcv ns3 protease inhibitors
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions